Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients.
Adult
Aged
COVID-19
/ complications
Factor Xa Inhibitors
/ therapeutic use
Female
Fondaparinux
/ therapeutic use
Humans
Male
Middle Aged
Multivariate Analysis
Proportional Hazards Models
Pulmonary Embolism
/ drug therapy
Pyridines
/ therapeutic use
Respiratory Distress Syndrome
Retrospective Studies
SARS-CoV-2
Thiazoles
/ therapeutic use
ARDS
COVID-19
SARS-CoV-2
edoxaban
efficacy
pulmonary embolism
safety
Journal
Expert review of clinical pharmacology
ISSN: 1751-2441
Titre abrégé: Expert Rev Clin Pharmacol
Pays: England
ID NLM: 101278296
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
pubmed:
18
8
2021
medline:
7
10
2021
entrez:
17
8
2021
Statut:
ppublish
Résumé
We aimed to investigate the clinical performance of edoxaban for the treatment of pulmonary embolism (PE) in hospitalized COVID-19 patients. We conducted a retrospective analysis selecting hospitalized patients with COVID-19 admitted to our Institution from 20 May 2020 to 20 November 2020 with computer tomography (CT) detected PE at admission, treated with edoxaban after initial parenteral therapy. Clinical outcomes were compared between patients with and without ARDS at admission and between those with and without CT confirmed PE resolution. 50 patients were included. Mean follow-up was 42.5 ± 10 days. No baseline differences were found between patients with ARDS (30%) and those without ARDS at admission. Patients with PE resolution (84%) were younger ( Edoxaban was an effective and safe treatment for acute PE in COVID-19 setting.
Identifiants
pubmed: 34402362
doi: 10.1080/17512433.2021.1964359
pmc: PMC8425471
doi:
Substances chimiques
Factor Xa Inhibitors
0
Pyridines
0
Thiazoles
0
Fondaparinux
J177FOW5JL
edoxaban
NDU3J18APO
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM